MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)

被引：72
|
作者：
Toffoli, G [1 ]
Veronesi, A
Boiocchi, M
Crivellari, D
机构：
[1] Natl Canc Inst, Ctr Riferimento Oncol, Div Expt Oncol 1, Aviano, PN, Italy
[2] Natl Canc Inst, Ctr Riferimento Oncol, Div Med Oncol C, Aviano, PN, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷 / 03期
关键词：
D O I：
10.1023/A:1008337900349
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：373 / 374
页数：2
相关论文
共 50 条
  • [31] TREATMENT OF METASTATIC BREAST-CANCER WITH CYCLOPHOSPHAMIDE, METHOTREXATE, VINCRISTINE AND FLUOROURACIL
    DELENA, M
    DEPALO, GM
    BONADONNA, G
    BERETTA, G
    BAJETTA, E
    TUMORI, 1973, 59 (01) : 11 - 24
  • [32] Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer
    Bonadonna, Gianni
    Valagussa, Pinuccia
    Veronesi, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) : 342 - 344
  • [33] The comparative study of adjuvant chemotherapy of breast cancer with cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus doxorubicin, cyclophosphamide (AC). First results of national cooperative study
    Pribylova, O
    Petruzelka, L
    Fischer, J
    Bustova, I
    Siffnerova, H
    Kuta, M
    Muller, V
    Hacklova, M
    Machacek, J
    Kohoutek, M
    Vodvarka, P
    Kysela, T
    Tajblova, J
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 811 - 815
  • [34] VARIABILITY IN THE PHARMACOKINETICS OF CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL IN WOMEN RECEIVING ADJUVANT TREATMENT FOR BREAST-CANCER
    MOORE, MJ
    ERLICHMAN, C
    THIESSEN, JJ
    BUNTING, PS
    HARDY, R
    KERR, I
    SOLDIN, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 33 (06) : 472 - 476
  • [35] Toxicity of concurrent adjuvant CMF chemotherapy and radiotherapy in patients with early breast cancer
    Yom, Cha-Kyong
    Kim, Hyun-Ah
    Moon, Byung-In
    Choe, Kuk-Jin
    Choi, Kum-Ja
    Suh, Hyun-Suk
    Choi, Hye-Young
    JOURNAL OF BREAST CANCER, 2007, 10 (02) : 147 - 152
  • [36] Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer
    Stevens, A
    Spooner, D
    CLINICAL ONCOLOGY, 2001, 13 (06) : 438 - 440
  • [37] ESTROGEN-RECEPTORS AND RESPONSE TO CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) IN ADVANCED BREAST-CANCER
    CHANG, JC
    HILL, GW
    WERGORSKI, G
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 411 - 411
  • [38] Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in Japanese patients with early breast cancer.
    Tada K.
    Ito Y.
    Takahashi S.
    Iijima K.
    Miyagi Y.
    Nishimura S.
    Takahashi K.
    Makita M.
    Iwase T.
    Yoshimoto M.
    Kasumi F.
    Breast Cancer, 2006, 13 (3) : 279 - 283
  • [39] THE EFFECT OF POSTOPERATIVE AND PRIMARY RADIATION-THERAPY ON DELIVERED DOSE OF ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL (CMF) CHEMOTHERAPY IN BREAST-CANCER
    LEVINE, JF
    COLEMAN, CN
    COX, RS
    RAY, GR
    ROGOWAY, WM
    MARTINEZ, A
    STOCKDALE, FE
    CANCER, 1984, 53 (02) : 237 - 241
  • [40] High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial
    Galligioni, E
    Cetto, G
    Nascimben, O
    Buonadaona, A
    Crivellari, D
    Molino, A
    Veronesi, A
    Graiff, C
    Barni, S
    Puccetti, C
    Ferrazzi, E
    Recaldin, E
    Sava, C
    Saracchini, S
    Sacco, C
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S36 - S36
12345